Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma
A Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of the PI3K/mTOR Inhibitor Paxalisib (GDC-0084) Administered to Patients With Glioblastoma Characterized by Unmethylated O6-methylguanine-methyltransferase Promoter Status Following Surgical Resection and Standard Concomitant Chemoradiation Therapy With Temozolomide
Sponsor: Kazia Therapeutics Limited
A PHASE2 clinical study on Glioblastoma, Adult, this trial is completed. The trial is conducted by Kazia Therapeutics Limited and has accumulated 15 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
15 versions recorded-
Apr 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Apr 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Apr 2023 — Apr 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 10 earlier versions
-
Sep 2022 — Apr 2023 [monthly]
Active Not Recruiting PHASE2
-
Oct 2021 — Sep 2022 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Apr 2020 — Jul 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Mar 2020 — Apr 2020 [monthly]
Recruiting PHASE2
-
Oct 2018 — Mar 2020 [monthly]
Recruiting PHASE2
-
Aug 2018 — Oct 2018 [monthly]
Recruiting PHASE2
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2
First recorded
May 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kazia Therapeutics Limited
For direct contact, visit the study record on ClinicalTrials.gov .